CHICAGO – The list of off-label uses for biologic agents is growing, and rheumatologists should stay abreast of even the nonrheumatologic uses, according to Dr. Eric Ruderman.
“My goal is to give you some guidance when somebody asks, because what you're going to find is that the dermatologists, ophthalmologists, and others are going to ask you as the rheumatologist, who is supposedly the expert in biologic therapy, what is the role for this, that, or the other drug,” said Dr. Ruderman, a rheumatologist at Northwestern University, Chicago.
There are scant data to support off-label uses, and these typically come from retrospective reports, small case series, or anecdotal experience, with a few exceptions, he said.
In dermatology, for example, infliximab is increasingly being used to treat hidradenitis suppurativa and neutrophilic dermatoses despite a lack of data from randomized controlled trials to support this practice. Findings from a small double-blind crossover trial involving 38 patients who were treated for 8 weeks, however, did suggest that infliximab improves pain, disease severity, and quality of life.
Some benefit was also shown with adalimumab in this disease in a recent case series, while benefits with etanercept were less clear in two open-label trials. Patients in the etanercept trials also had worsening of their condition after etanercept was discontinued.
As for neutrophilic dermatoses, infliximab appears to be useful for pyoderma gangrenosum and possibly for Sweet's syndrome. In a double-blind study of 30 patients with pyoderma gangrenosum, a single dose of 5 mg/kg was associated with a 46% improvement, compared with 6% for placebo. Furthermore, nonresponders on placebo at 2 weeks were treated with infliximab with a 60% response rate, and 21% of treated patients achieved remission.
Biologic therapies being used for ophthalmologic conditions include infliximab, adalimumab, and/or daclizumab for childhood uveitis and other types of uveitis, Dr. Ruderman noted.
Retrospective case series have shown benefit with infliximab, adalimumab, and daclizumab in childhood uveitis, and an open-label prospective study comparing adalimumab and infliximab demonstrated greater benefit with adalimumab (60% vs. 20% remission at 40 months), he said.
Infliximab also may have some benefit in ocular sarcoidosis, with case reports and small open-label series demonstrating some benefit. Etanercept in this disease, however, appears to be no more effective than placebo, based on findings of a randomized study of 18 patients treated for 6 months.
In Behçet's uveitis, case reports and findings from two small open trials suggest some benefit with infliximab. In the open trials, 9 of 12 patients responded to a dose of 5 mg/kg, Dr. Ruderman said, adding that treatment helped reduce steroid use, but relapse was frequent after treatment discontinuation, suggesting that ongoing therapy is necessary.
Other conditions in which biologics are currently being used include pulmonary and extrapulmonary sarcoidosis, asthma, and chronic obstructive pulmonary disease (COPD).
In one “nicely done” randomized, controlled, multicenter study of 138 pulmonary sarcoidosis patients, infliximab was superior to placebo for improving the percent predicted forced vital capacity at 24 weeks, and also led to improvement in extrapulmonary disease, Dr. Ruderman said.
Improvements in scores on the extrapulmonary physician organ severity tool (ePOST) were better in the treatment versus placebo group at 24 weeks, even after adjusting for the number of organs involved, he said.
Findings from an open-label study of etanercept in this disease, however, showed that only 5 of 17 patients had “success,” which was defined as lack of deterioration on x-rays or pulmonary function tests.
Case reports and retrospective data – but not randomized controlled data – have also shown some benefit of infliximab for cutaneous sarcoidosis. In 54 patients who received 116 courses of therapy, resolution or near resolution of lupus pernio was achieved in 77% of patients versus 11%–29% of those treated with steroids and other therapy. Some case reports show benefit in neurosarcoidosis, as well, but no solid data are available to back those up, Dr. Ruderman said.
For asthma, there may be a role for tumor necrosis factor inhibitors, although one randomized controlled trial showed no benefit with golimumab.
The Brigham RA Sequential Study, for example, demonstrated improvement with TNF inhibitors in nine patients with both rheumatoid arthritis and asthma; findings from a small, controlled trial of etanercept showed some benefit on several measures of response. The benefits in that study, however, were not clear-cut, and two other etanercept trials, as well as one infliximab trial, failed to show any benefit in asthma.
Similarly, golimumab showed no benefit in a 52-week randomized controlled trial of 231 patients with severe uncontrolled asthma. Those patients had no improvements over placebo in forced expiratory volume in 1 second (FEV1) or exacerbations and experienced frequent severe infections, Dr. Ruderman said.